Faron Pharmaceuticals Oy (LON:FARN - Get Free Report) shares crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 176.23 ($2.29) and traded as high as GBX 220 ($2.86). Faron Pharmaceuticals Oy shares last traded at GBX 202.75 ($2.63), with a volume of 25,650 shares.
Faron Pharmaceuticals Oy Trading Up 2.9 %
The company has a debt-to-equity ratio of 922.55, a current ratio of 1.45 and a quick ratio of 1.09. The firm's fifty day moving average is GBX 177.45 and its 200-day moving average is GBX 184.80. The firm has a market cap of £288.64 million, a price-to-earnings ratio of -5.75 and a beta of 0.36.
About Faron Pharmaceuticals Oy
(
Get Free Report)
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Read More
Before you consider Faron Pharmaceuticals Oy, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Faron Pharmaceuticals Oy wasn't on the list.
While Faron Pharmaceuticals Oy currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
